If not for the intentional dose switching, a non-PPHM issue, we would have been at $10+ with 109% and an approved phase lll trial. That would be 250% and very much in line with a real valuation for a buyout.
Some type of announcement like BTD and pps goes to $3. Rumors start about buyout with real leaks and pps goes $8. Buyout at $25 and it fits right into your table at 212% premium over the $8 price.
You and I know the uyout offer would not come when the pps was at $1.29. A few other things would happen before the buyout rumor leak and then actual buyout announcement.
Dew...i'd be happy with $6, a share price that could come quickly if they manage to work out a partnership with an outfit somebody's heard of... after all, they've been 'in talks' for quite some time already!
About DD's comments about the buyout... I wonder why considering a buyout of a "placebo" making company... Why even bother writting about it!! Too much iddle time? or it is no longer a placebo? FDA does not seem to think so. So "a placebo" or not "a placebo" that is the question!!!